GlassScriptPhysician profile
Theodore Jones
NPI 1508857483
$4,697.68
in general payments reported to CMS, 2019-2025
26 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $407 · 2021: $697 · 2022: $1,035 · 2023: $655 · 2024: $699 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,174.07 | 2019-2025 | Tryptyr, Simbrinza, Clareon |
| Abbvie INC. | $874.46 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $307.80 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $294.17 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $260.94 | 2019-2025 | Cequa |
| Allergan, INC. | $217.62 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $214.10 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $180.17 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.59 | 2019-2021 | |
| Oyster Point Pharma, INC. | $157.53 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $149.05 | 2022-2025 | Oxervate |
| Shire North American Group INC | $88.02 | 2019 | |
| Glaukos Corporation | $85.94 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Biotissue Holdings INC. | $84.89 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $78.91 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $71.88 | 2019-2021 | |
| Ocular Therapeutix, INC. | $45.46 | 2021-2024 | Dextenza |
| Thea Pharma INC. | $39.79 | 2025 | Iyuzeh |
| Harrow Eye, LLC | $39.27 | 2025 | Iheezo |
| Amgen INC. | $35.92 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $33.15 | 2021-2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $28.03 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Sight Sciences, INC. | $19.58 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Rxsight INC | $19.57 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Omeros Corporation | $17.95 | 2021 | |
| Tearlab Corp | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.